Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05757869 · ClinicalTrials.gov registry record · Phase 3
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
A Phase 3 study of Atrial Fibrillation, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 20,284
- Enrollment target
- 20
- Study locations
NCT05757869 is a Phase 3 study of Atrial Fibrillation that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 20,284 participants, above the 2,896-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (600% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT05757869, a Phase 3 study of Atrial Fibrillation, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 20,284 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Apixaban
- DRUG Milvexian
- DRUG Apixaban Placebo
Study Locations (20)
California
- Bakersfield Memorial Hospital - Bakersfield
- Vitality Clinical Research - Beverly Hills
- Chula Vista Cardiac Clinic - Chula Vista
- Sharp Chula Vista Medical Center - Chula Vista
- Mission Cardiovascular Research Institute - Fremont
- Paradise Clinical Research Group LLC - Glendora
- Miller Children's at Long Beach Medical Center - Long Beach
- Los Angeles Cardiology Associates - Los Angeles
- University of Southern California - Los Angeles
Alabama
- Advanced Cardiovascular, LLC - Alexander City
- Ascension St. Vincent's Health System - Birmingham
- SEC Clinical Research - Dothan
- HH Heart Center and Heart Center - Huntsville
- CB Flock Research Corporation - Mobile
Arizona
- Mercy Gilbert Medical Center - Gilbert
- Valleywise Health Medical Center - Phoenix
- Arizona Arrhythmia Research Center - Phoenix
- Arizona Heart Hospital - Phoenix
- HonorHealth Neurology - Scottsdale
Arkansas
- Arkansas Heart Hospital - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20,284 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2026-10-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05757869
The ClinicalTrials.gov registry entry for NCT05757869 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 20,284 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,896-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (600% higher). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT05757869 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT05757869 about?
NCT05757869 is a clinical study titled "A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation". The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
What is the current status of trial NCT05757869?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 20,284 participants. The study started on 2023-04-11. Estimated completion is 2026-10-31.
What conditions does trial NCT05757869 study?
This clinical trial studies the following conditions: Atrial Fibrillation.
What interventions are being tested in trial NCT05757869?
The interventions under investigation include: Placebo (DRUG), Apixaban (DRUG), Milvexian (DRUG), Apixaban Placebo (DRUG).
Who is sponsoring clinical trial NCT05757869?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05757869 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
RECRUITING · Phase 3
-
Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
RECRUITING · Phase 3
-
Dapagliflozin in Patients With Atrial Fibrillation (DAPA-AF)
RECRUITING · Phase 3
-
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.